

Thomas K Karikari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7861842/publications.pdf>

Version: 2024-02-01

382
papers

20,740
citations

17429

63
h-index

16164

124
g-index

422
all docs

422
docs citations

422
times ranked

22377
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates APOE, tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
2	Analysis of shared heritability in common disorders of the brain. <i>Science</i> , 2018, 360, .	6.0	1,085
3	The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. <i>Brain</i> , 2020, 143, 3104-3120.	3.7	880
4	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	9.4	700
5	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , The, 2020, 19, 422-433.	4.9	668
6	Posterior cortical atrophy. <i>Lancet Neurology</i> , The, 2012, 11, 170-178.	4.9	487
7	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , The, 2017, 16, 661-676.	4.9	464
8	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
9	Consensus classification of posterior cortical atrophy. <i>Alzheimer's and Dementia</i> , 2017, 13, 870-884.	0.4	423
10	Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. <i>Neurology</i> , 2016, 87, 1329-1336.	1.5	354
11	Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 66-75.	4.9	304
12	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021, 141, 709-724.	3.9	285
13	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. <i>Nature Communications</i> , 2018, 9, 4273.	5.8	263
14	A data-driven model of biomarker changes in sporadic Alzheimer's disease. <i>Brain</i> , 2014, 137, 2564-2577.	3.7	243
15	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021, 27, 1592-1599.	15.2	235
16	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	5.8	219
17	New insights into atypical Alzheimer's disease in the era of biomarkers. <i>Lancet Neurology</i> , The, 2021, 20, 222-234.	4.9	214
18	CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. <i>Neurology</i> , 2014, 83, 1945-1953.	1.5	213

#	ARTICLE	IF	CITATIONS
19	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> , 2020, 140, 267-278.	3.9	209
20	Serum neurofilament light in familial Alzheimer disease. <i>Neurology</i> , 2017, 89, 2167-2175.	1.5	204
21	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021, 78, 1471.	4.5	204
22	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A β pathology are detected. <i>EMBO Molecular Medicine</i> , 2020, 12, e12921.	3.3	202
23	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021, 26, 429-442.	4.1	186
24	Primary progressive aphasia: a clinical approach. <i>Journal of Neurology</i> , 2018, 265, 1474-1490.	1.8	185
25	Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. <i>Lancet Neurology</i> , 2019, 18, 942-952.	4.9	178
26	MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. <i>Brain</i> , 2016, 139, 1211-1225.	3.7	174
27	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1145-1156.	0.4	174
28	Increased CSF neurogranin concentration is specific to Alzheimer disease. <i>Neurology</i> , 2016, 86, 829-835.	1.5	170
29	Molecular biomarkers of Alzheimer's disease: progress and prospects. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	163
30	Characterization of tau positron emission tomography tracer [¹⁸ F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. <i>Alzheimer's and Dementia</i> , 2016, 12, 1116-1124.	0.4	161
31	Assessing the onset of structural change in familial Alzheimer's disease. <i>Annals of Neurology</i> , 2003, 53, 181-188.	2.8	152
32	Cerebrospinal fluid tau and amyloid- β ₁₋₄₂ in patients with dementia. <i>Brain</i> , 2015, 138, 2716-2731.	3.7	152
33	Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid A β ₁₋₄₂ . <i>Annals of Neurology</i> , 2010, 68, 825-834.	2.8	150
34	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	4.5	146
35	Prevalence of amyloid- β pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.	2.8	132
36	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , 2021, 144, 325-339.	3.7	124

#	ARTICLE	IF	CITATIONS
37	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. <i>Molecular Neurodegeneration</i> , 2015, 10, 64.	4.4	121
38	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 265-284.	4.9	121
39	Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1225-1233.	0.9	114
40	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. <i>JAMA Neurology</i> , 2021, 78, 1108.	4.5	114
41	Data-driven models of dominantly-inherited Alzheimer's disease progression. <i>Brain</i> , 2018, 141, 1529-1544.	3.7	111
42	Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. <i>Molecular Psychiatry</i> , 2020, 25, 2919-2931.	4.1	99
43	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. <i>Nature Reviews Neurology</i> , 2022, 18, 400-418.	4.9	99
44	Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 708-713.	0.9	97
45	R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2014, 10, 602.	0.4	94
46	Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 487-496.	0.4	94
47	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 862-871.	0.4	93
48	Diagnostic and prognostic value of serum NfL and p-Tau ₁₈₁ in frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 960-967.	0.9	93
49	Pain and temperature processing in dementia: a clinical and neuroanatomical analysis. <i>Brain</i> , 2015, 138, 3360-3372.	3.7	90
50	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1141-1154.	0.4	89
51	Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. <i>Acta Neuropathologica</i> , 2022, 143, 487-503.	3.9	89
52	Cortical microstructure in young onset Alzheimer's disease using neurite orientation dispersion and density imaging. <i>Human Brain Mapping</i> , 2018, 39, 3005-3017.	1.9	87
53	Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic era. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 543-555.	0.9	87
54	Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , The, 2018, 17, 123-132.	4.9	84

#	ARTICLE	IF	CITATIONS
55	Functional cognitive disorder: dementia's blind spot. <i>Brain</i> , 2020, 143, 2895-2903.	3.7	84
56	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2140-2156.	3.3	83
57	ApoE influences regional white-matter axonal density loss in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 57, 8-17.	1.5	82
58	Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2021, 17, 755-767.	0.4	81
59	Mild Cognitive Impairment: the Manchester consensus. <i>Age and Ageing</i> , 2021, 50, 72-80.	0.7	80
60	Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 32.	3.0	79
61	Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 908-916.	0.9	78
62	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. <i>Molecular Psychiatry</i> , 2021, 26, 5967-5976.	4.1	76
63	Abnormalities of fixation, saccade and pursuit in posterior cortical atrophy. <i>Brain</i> , 2015, 138, 1976-1991.	3.7	74
64	Clinical and genetic characterization of leukoencephalopathies in adults. <i>Brain</i> , 2017, 140, 1204-1211.	3.7	73
65	Biomarker modeling of Alzheimer's disease using PET-based Braak staging. <i>Nature Aging</i> , 2022, 2, 526-535.	5.3	73
66	Algorithms, atrophy and Alzheimer's disease: Cautionary tales for clinical trials. <i>NeuroImage</i> , 2011, 57, 15-18.	2.1	69
67	Diffuse axonal injury predicts neurodegeneration after moderate-to-severe traumatic brain injury. <i>Brain</i> , 2020, 143, 3685-3698.	3.7	69
68	White matter tract signatures of impaired social cognition in frontotemporal lobar degeneration. <i>NeuroImage: Clinical</i> , 2015, 8, 640-651.	1.4	65
69	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 19.	3.0	65
70	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. <i>EBioMedicine</i> , 2022, 76, 103836.	2.7	65
71	Brain biopsy in dementia: clinical indications and diagnostic approach. <i>Acta Neuropathologica</i> , 2010, 120, 327-341.	3.9	64
72	Redefining the phenotype of ALS and AARS2 mutation-related leukodystrophy. <i>Neurology: Genetics</i> , 2017, 3, e135.	0.9	64

#	ARTICLE	IF	CITATIONS
73	Study protocol: Insight 46 – a neuroscience sub-study of the MRC National Survey of Health and Development. <i>BMC Neurology</i> , 2017, 17, 75.	0.8	64
74	Longitudinal neuroanatomical and cognitive progression of posterior cortical atrophy. <i>Brain</i> , 2019, 142, 2082-2095.	3.7	64
75	Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. <i>NeuroImage</i> , 2015, 123, 149-164.	2.1	63
76	Effect of Race on Prediction of Brain Amyloidosis by Plasma A β ₄₂ /A β ₄₀ , Phosphorylated Tau, and Neurofilament Light. <i>Neurology</i> , 2022, 99, .	1.5	63
77	Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1000-1004.	0.9	62
78	Presymptomatic cortical thinning in familial Alzheimer disease. <i>Neurology</i> , 2016, 87, 2050-2057.	1.5	58
79	Genetic study of multimodal imaging Alzheimer's disease progression score implicates novel loci. <i>Brain</i> , 2018, 141, 2167-2180.	3.7	56
80	CSF Beta-amyloid 1 β 42 Concentration Predicts Delirium Following Elective Arthroplasty Surgery in an Observational Cohort Study. <i>Annals of Surgery</i> , 2019, 269, 1200-1205.	2.1	56
81	Associations Between Vascular Risk Across Adulthood and Brain Pathology in Late Life. <i>JAMA Neurology</i> , 2020, 77, 175.	4.5	55
82	Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1129-1141.	1.2	55
83	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2021, 290, 583-601.	2.7	54
84	OUP accepted manuscript. <i>Brain</i> , 2021, 144, 434-449.	3.7	54
85	Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 3140-3151.	1.5	53
86	Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12168.	1.2	52
87	Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study. <i>Brain</i> , 2010, 133, 3315-3322.	3.7	51
88	Population Screening for Variant Creutzfeldt-Jakob Disease Using a Novel Blood Test. <i>JAMA Neurology</i> , 2014, 71, 421.	4.5	51
89	Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1231-1241.	0.9	51
90	Eyetracking Metrics in Young Onset Alzheimer's Disease: A Window into Cognitive Visual Functions. <i>Frontiers in Neurology</i> , 2017, 8, 377.	1.1	50

#	ARTICLE	IF	CITATIONS
91	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. <i>Neurology</i> , 2021, 97, .	1.5	50
92	Auditory spatial processing in Alzheimer's disease. <i>Brain</i> , 2015, 138, 189-202.	3.7	49
93	Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 448-451.	1.2	49
94	Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 65.	3.0	49
95	The accuracy and robustness of plasma biomarker models for amyloid PET positivity. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 26.	3.0	49
96	Auditory hedonic phenotypes in dementia: A behavioural and neuroanatomical analysis. <i>Cortex</i> , 2015, 67, 95-105.	1.1	48
97	Aducanumab: a new phase in therapeutic development for Alzheimer's disease?. <i>EMBO Molecular Medicine</i> , 2021, 13, e14781.	3.3	47
98	Beyond the average patient: how neuroimaging models can address heterogeneity in dementia. <i>Brain</i> , 2021, 144, 2946-2953.	3.7	46
99	The Dementias Platform UK (DPUK) Data Portal. <i>European Journal of Epidemiology</i> , 2020, 35, 601-611.	2.5	45
100	A comprehensive analysis of methods for assessing polygenic burden on Alzheimer's disease pathology and risk beyond APOE. <i>Brain Communications</i> , 2020, 2, fcz047.	1.5	45
101	Bioinformatics in Africa: The Rise of Ghana?. <i>PLoS Computational Biology</i> , 2015, 11, e1004308.	1.5	45
102	Functional neuroanatomy of auditory scene analysis in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2015, 7, 699-708.	1.4	43
103	Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 79.	3.0	43
104	Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. <i>Brain Communications</i> , 2021, 3, fcab099.	1.5	43
105	Humour processing in frontotemporal lobar degeneration: A behavioural and neuroanatomical analysis. <i>Cortex</i> , 2015, 69, 47-59.	1.1	42
106	Data-Driven Sequence of Changes to Anatomical Brain Connectivity in Sporadic Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 580.	1.1	42
107	Introduction of Tau Oligomers into Cortical Neurons Alters Action Potential Dynamics and Disrupts Synaptic Transmission and Plasticity. <i>ENeuro</i> , 2019, 6, ENEURO.0166-19.2019.	0.9	42
108	Plasma p-tau231, p-tau181, <sc>PET</sc> Biomarkers, and Cognitive Change in Older Adults. <i>Annals of Neurology</i> , 2022, 91, 548-560.	2.8	42

#	ARTICLE	IF	CITATIONS
109	Susceptibility of brain atrophy to <i>TRIB3</i> in Alzheimer's disease, evidence from functional prioritization in imaging genetics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3162-3167.	3.3	41
110	Plasma tau is increased in frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 804-807.	0.9	41
111	Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 62.	3.0	40
112	Amyloid-beta 42 adsorption following serial tube transfer. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 5.	3.0	39
113	Altered Sense of Humor in Dementia. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 111-119.	1.2	39
114	Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. <i>Journal of Neurology</i> , 2015, 262, 2722-2730.	1.8	39
115	Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial. <i>Brain Stimulation</i> , 2020, 13, 1031-1039.	0.7	39
116	Inflammation in Alzheimer's disease: insights from immunotherapy. <i>Brain</i> , 2013, 136, 2654-2656.	3.7	38
117	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1189-1201.	1.2	38
118	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2022, 79, 32.	4.5	38
119	Social Factors Influencing Child Health in Ghana. <i>PLoS ONE</i> , 2016, 11, e0145401.	1.1	37
120	Using a birth cohort to study brain health and preclinical dementia: recruitment and participation rates in Insight 46. <i>BMC Research Notes</i> , 2018, 11, 885.	0.6	37
121	Cognition at age 70. <i>Neurology</i> , 2019, 93, e2144-e2156.	1.5	37
122	SILK studies " capturing the turnover of proteins linked to neurodegenerative diseases. <i>Nature Reviews Neurology</i> , 2019, 15, 419-427.	4.9	37
123	Differences in hippocampal subfield volume are seen in phenotypic variants of early onset Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 21, 101632.	1.4	37
124	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimer's and Dementia</i> , 2019, 15, 388-399.	0.4	37
125	Plasma τ_{181} to τ_{42} ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1649-1662.	0.4	37
126	Genetic Influences on Atrophy Patterns in Familial Alzheimer's Disease: A Comparison of APP and PSEN1 Mutations. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 199-212.	1.2	36

#	ARTICLE	IF	CITATIONS
127	Prominent effects and neural correlates of visual crowding in a neurodegenerative disease population. <i>Brain</i> , 2014, 137, 3284-3299.	3.7	36
128	Distinct Conformations, Aggregation and Cellular Internalization of Different Tau Strains. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 296.	1.8	36
129	Expression and purification of tau protein and its frontotemporal dementia variants using a cleavable histidine tag. <i>Protein Expression and Purification</i> , 2017, 130, 44-54.	0.6	35
130	Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. <i>F1000Research</i> , 2017, 6, 1604.	0.8	35
131	Preparation of stable tau oligomers for cellular and biochemical studies. <i>Analytical Biochemistry</i> , 2019, 566, 67-74.	1.1	35
132	Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 17.	3.0	35
133	Amyloid processing in COVID-19-associated neurological syndromes. <i>Journal of Neurochemistry</i> , 2022, 161, 146-157.	2.1	35
134	Music Perception in Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 933-949.	1.2	34
135	Assessment of the quality of groundwater for drinking purposes in the Upper West and Northern regions of Ghana. <i>SpringerPlus</i> , 2016, 5, 2001.	1.2	34
136	Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. <i>Neurobiology of Aging</i> , 2016, 39, 99-107.	1.5	34
137	Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 382-387.	1.8	34
138	Biomarkers for Alzheimer's disease beyond amyloid and tau. <i>Nature Medicine</i> , 2019, 25, 201-203.	15.2	34
139	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 69.	3.0	34
140	Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. <i>EBioMedicine</i> , 2022, 76, 103837.	2.7	34
141	Association of plasma P-tau181 with memory decline in non-demented adults. <i>Brain Communications</i> , 2021, 3, fcab136.	1.5	33
142	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304.	5.8	33
143	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 20.	3.0	32
144	Altered body schema processing in frontotemporal dementia with C9ORF72 mutations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1016-1023.	0.9	31

#	ARTICLE	IF	CITATIONS
145	Motor signatures of emotional reactivity in frontotemporal dementia. <i>Scientific Reports</i> , 2018, 8, 1030.	1.6	31
146	Commentary: Global, regional, and national burden of neurological disorders during 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Frontiers in Neurology</i> , 2018, 9, 201.	1.1	31
147	CSF synaptic protein concentrations are raised in those with atypical Alzheimerâ€™s disease but not frontotemporal dementia. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 105.	3.0	31
148	Unsuccessful trials of therapies for Alzheimer's disease. <i>Lancet, The</i> , 2019, 393, 29.	6.3	31
149	Building sustainable neuroscience capacity in Africa: the role of non-profit organisations. <i>Metabolic Brain Disease</i> , 2016, 31, 3-9.	1.4	30
150	CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 162-171.	1.7	30
151	Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. <i>Molecular Psychiatry</i> , 2021, 26, 5955-5966.	4.1	30
152	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	0.9	30
153	Pâ€tau235: a novel biomarker for staging preclinical Alzheimerâ€™s disease. <i>EMBO Molecular Medicine</i> , 2021, 13, e15098.	3.3	30
154	Motor Neuron Diseases in Sub-Saharan Africa: The Need for More Population-Based Studies. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	29
155	Blood Biomarkers for Alzheimerâ€™s Disease: Much Promise, Cautious Progress. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 13-22.	1.6	29
156	Developing expertise in bioinformatics for biomedical research in Africa. <i>Applied & Translational Genomics</i> , 2015, 6, 31-34.	2.1	28
157	Medicinal Plants Used in the Treatment of Mental and Neurological Disorders in Ghana. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-14.	0.5	28
158	Blood biomarkers for Alzheimer's disease and related disorders. <i>Acta Neurologica Scandinavica</i> , 2022, 146, 51-55.	1.0	28
159	Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 56-76.	0.7	27
160	Hippocampal subfield volumes and pre-clinical Alzheimerâ€™s disease in 408 cognitively normal adults born in 1946. <i>PLoS ONE</i> , 2019, 14, e0224030.	1.1	26
161	Genetic testing in dementia â€” utility and clinical strategies. <i>Nature Reviews Neurology</i> , 2021, 17, 23-36.	4.9	26
162	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.4	26

#	ARTICLE	IF	CITATIONS
163	Islet amyloid polypeptide-induced cerebral amyloid angiopathy: an emerging clinical phenomenon. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 693-700.	0.9	26
164	New developments in mild cognitive impairment and Alzheimer's disease. <i>Current Opinion in Neurology</i> , 2006, 19, 552-558.	1.8	25
165	Using CSF biomarkers to replicate genetic associations in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1486.e9-1486.e15.	1.5	25
166	Functional neuroanatomy of spatial sound processing in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 39, 154-164.	1.5	25
167	Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 65.	3.0	25
168	ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid- β copathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 277-280.	1.2	24
169	Identification of environmental sounds and melodies in syndromes of anterior temporal lobe degeneration. <i>Journal of the Neurological Sciences</i> , 2015, 352, 94-98.	0.3	23
170	Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 740-746.	0.9	23
171	CSF biomarkers and plasma τ 181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. <i>Alzheimer's and Dementia</i> , 2022, 18, 2614-2626.	0.4	22
172	Dementias show differential physiological responses to salient sounds. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 73.	1.0	21
173	Neurogenomics: An opportunity to integrate neuroscience, genomics and bioinformatics research in Africa. <i>Applied & Translational Genomics</i> , 2015, 5, 3-10.	2.1	21
174	Physiological phenotyping of dementias using emotional sounds. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 170-178.	1.2	21
175	Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1297-1302.	1.2	21
176	Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 311-321.	1.2	21
177	Inhibiting the Ca ²⁺ Influx Induced by Human CSF. <i>Cell Reports</i> , 2017, 21, 3310-3316.	2.9	20
178	The functional neuroanatomy of musical memory in Alzheimer's disease. <i>Cortex</i> , 2019, 115, 357-370.	1.1	20
179	Understanding the Pathophysiological Actions of Tau Oligomers: A Critical Review of Current Electrophysiological Approaches. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 155.	1.4	20
180	A blood miRNA signature associates with sporadic Creutzfeldt-Jakob disease diagnosis. <i>Nature Communications</i> , 2020, 11, 3960.	5.8	20

#	ARTICLE	IF	CITATIONS
181	N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. <i>Brain</i> , 2022, 145, 2834-2848.	3.7	20
182	Delineating the sites and progression of in vivo atrophy in multiple system atrophy using fluid-registered MRI. <i>Movement Disorders</i> , 2003, 18, 955-958.	2.2	19
183	Alzheimer's disease: mimics and chameleons. <i>Practical Neurology</i> , 2012, 12, 358-366.	0.5	19
184	Differential hippocampal shapes in posterior cortical atrophy patients: A comparison with control and typical <sc>AD</sc> subjects. <i>Human Brain Mapping</i> , 2015, 36, 5123-5136.	1.9	19
185	Automated quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater, clinical accuracy study. <i>European Radiology</i> , 2021, 31, 5312-5323.	2.3	19
186	Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12131.	1.2	19
187	A physiological signature of sound meaning in dementia. <i>Cortex</i> , 2016, 77, 13-23.	1.1	18
188	Multimodal Image Analysis in Alzheimer's Disease via Statistical Modelling of Non-local Intensity Correlations. <i>Scientific Reports</i> , 2016, 6, 22161.	1.6	18
189	Academic dishonesty in higher education: students' perceptions and involvement in an African institution. <i>BMC Research Notes</i> , 2016, 9, 234.	0.6	18
190	Construction and reconstruction of brain circuits: normal and pathological axon guidance. <i>Journal of Neurochemistry</i> , 2020, 153, 10-32.	2.1	18
191	Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 112.	3.0	18
192	Altered DNA methylation profiles in blood from patients with sporadic Creutzfeldt-Jakob disease. <i>Acta Neuropathologica</i> , 2020, 140, 863-879.	3.9	18
193	Grip strength from midlife as an indicator of later-life brain health and cognition: evidence from a British birth cohort. <i>BMC Geriatrics</i> , 2021, 21, 475.	1.1	18
194	Loss and dispersion of superficial white matter in Alzheimer's disease: a diffusion MRI study. <i>Brain Communications</i> , 2021, 3, fcab272.	1.5	18
195	Plasma τ_{181} shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau. <i>Alzheimer's and Dementia</i> , 2022, 18, 1523-1536.	0.4	18
196	Extract of <i>Synedrella nodiflora</i> (L) Gaertn exhibits antipsychotic properties in murine models of psychosis. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 389.	3.7	17
197	Cerebrospinal Fluid Spermidine, Glutamine and Putrescine Predict Postoperative Delirium Following Elective Orthopaedic Surgery. <i>Scientific Reports</i> , 2019, 9, 4191.	1.6	17
198	Sleep symptoms in syndromes of frontotemporal dementia and Alzheimer's disease: A proof-of-principle behavioural study. <i>ENeurologicalSci</i> , 2019, 17, 100212.	0.5	17

#	ARTICLE	IF	CITATIONS
199	The global Alzheimer's Association round robin study on plasma amyloid β^2 methods. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12242.	1.2	17
200	Circulating Metabolome and White Matter Hyperintensities in Women and Men. <i>Circulation</i> , 2022, 145, 1040-1052.	1.6	17
201	Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 440-446.	1.2	16
202	Incidental findings on brain imaging and blood tests: results from the first phase of Insight 46, a prospective observational substudy of the 1946 British birth cohort. <i>BMJ Open</i> , 2019, 9, e029502.	0.8	16
203	Pure tone audiometry and cerebral pathology in healthy older adults. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 172-176.	0.9	16
204	Subjective cognitive complaints at age 70: associations with amyloid and mental health. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1215-1221.	0.9	16
205	Dissociable effects of APOE ϵ^4 and β^2 -amyloid pathology on visual working memory. <i>Nature Aging</i> , 2021, 1, 1002-1009.	5.3	16
206	Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 182-192.	0.7	16
207	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. <i>Brain Communications</i> , 2021, 3, fcab073.	1.5	15
208	Mild Parkinsonian Signs: A Systematic Review of Clinical, Imaging, and Pathological Associations. <i>Movement Disorders</i> , 2021, 36, 2481-2493.	2.2	15
209	Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy. <i>Brain</i> , 2022, 145, 3546-3557.	3.7	15
210	The habenula: an under-recognised area of importance in frontotemporal dementia?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 910-912.	0.9	14
211	A Comparison of Accelerated and Non-accelerated MRI Scans for Brain Volume and Boundary Shift Integral Measures of Volume Change: Evidence from the ADNI Dataset. <i>Neuroinformatics</i> , 2017, 15, 215-226.	1.5	14
212	A simulation system for biomarker evolution in neurodegenerative disease. <i>Medical Image Analysis</i> , 2015, 26, 47-56.	7.0	13
213	New criteria for Alzheimer's disease: which, when and why?. <i>Brain</i> , 2015, 138, 1134-1137.	3.7	12
214	Disregard of neurological impairments associated with neglected tropical diseases in Africa. <i>ENeurologicalSci</i> , 2016, 3, 11-14.	0.5	12
215	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for <i>C9orf72</i> -associated frontotemporal dementia and amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 761-771.	0.9	12
216	Associations of β^2 -Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal Members of the 1946 British Birth Cohort. <i>Neurology</i> , 2022, 99, .	1.5	12

#	ARTICLE	IF	CITATIONS
217	Comorbidities confound Alzheimer's blood tests. <i>Nature Medicine</i> , 2022, 28, 1349-1351.	15.2	12
218	Effect of age at onset on cortical thickness and cognition in posterior cortical atrophy. <i>Neurobiology of Aging</i> , 2016, 44, 108-113.	1.5	11
219	Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASL-MRI: proof of concept. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2419-2432.	2.4	11
220	Differences in topological progression profile among neurodegenerative diseases from imaging data. <i>ELife</i> , 2019, 8, .	2.8	11
221	Potential role of metabolomics in the improvement of research on traditional African medicine. <i>Phytochemistry Letters</i> , 2016, 17, 270-277.	0.6	10
222	The C291R Tau Variant Forms Different Types of Protofibrils. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 39.	1.4	10
223	KL-VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE-4 carriers. <i>Neurobiology of Aging</i> , 2021, 101, 123-129.	1.5	10
224	Letter to the Editor. <i>Journal of Microbiology and Biology Education</i> , 2015, 16, 3-4.	0.5	9
225	A novel use of arterial spin labelling MRI to demonstrate focal hypoperfusion in individuals with posterior cortical atrophy: a multimodal imaging study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1032-1034.	0.9	9
226	Neuroscience-related research in Ghana: a systematic evaluation of direction and capacity. <i>Metabolic Brain Disease</i> , 2016, 31, 11-24.	1.4	9
227	Cerebrospinal fluid in the dementias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 146, 85-97.	1.0	9
228	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease. <i>Clinical Mass Spectrometry</i> , 2019, 14, 74-82.	1.9	9
229	Apolipoprotein E genotypes and longevity across dementia disorders. <i>Alzheimer's and Dementia</i> , 2018, 14, 895-901.	0.4	8
230	An extract of <i>Synedrella nodiflora</i> (L) Gaertn exhibits antidepressant properties through monoaminergic mechanisms. <i>Metabolic Brain Disease</i> , 2018, 33, 1359-1368.	1.4	8
231	Increased variability in reaction time is associated with amyloid beta pathology at age 70. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12076.	1.2	8
232	Investigating the Relationship Between IGF-I, IGF-II, and IGFBP-3 Concentrations and Later-Life Cognition and Brain Volume. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1617-1629.	1.8	8
233	Visuomotor integration deficits are common to familial and sporadic preclinical Alzheimer's disease. <i>Brain Communications</i> , 2021, 3, fcab003.	1.5	8
234	Prodromal frontotemporal dementia: clinical features and predictors of progression. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 188.	3.0	8

#	ARTICLE	IF	CITATIONS
235	Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-8.	1.2	8
236	Prion disease diagnosis using subject-specific imaging biomarkers within a multi-kernel Gaussian process. <i>NeuroImage: Clinical</i> , 2019, 24, 102051.	1.4	7
237	Investigating the relationship between BMI across adulthood and late life brain pathologies. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 91.	3.0	7
238	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	7
239	Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid- β Concentration. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 885-891.	1.2	6
240	Extensive Plasmid Library to Prepare Tau Protein Variants and Study Their Functional Biochemistry. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3117-3129.	1.7	6
241	Bridging the gap: Introducing neuroscience to Ghana. <i>Biochemist</i> , 2015, 37, 46-47.	0.2	6
242	Suspected early dementia. <i>BMJ: British Medical Journal</i> , 2011, 343, d5568-d5568.	2.4	5
243	Do cerebrospinal fluid transfer methods affect measured amyloid β ⁴² , total tau, and phosphorylated tau in clinical practice?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 380-384.	1.2	5
244	The palmomental reflex: stop scratching around!. <i>Practical Neurology</i> , 2016, 16, 500-501.	0.5	5
245	A population-based study of head injury, cognitive function and pathological markers. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 842-856.	1.7	5
246	Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis. <i>Journal of Neurology</i> , 2022, 269, 1470-1475.	1.8	5
247	A genome-wide association study of plasma phosphorylated tau ¹⁸¹ . <i>Neurobiology of Aging</i> , 2021, 106, 304.e1-304.e3.	1.5	5
248	Evaluation of Changes in Ghanaian Students' Attitudes Towards Science Following Neuroscience Outreach Activities: A Means to Identify Effective Ways to Inspire Interest in Science Careers. <i>Journal of Undergraduate Neuroscience Education: JUNE: A Publication of FUN, Faculty for Undergraduate Neuroscience</i> , 2016, 14, A117-23.	0.6	5
249	Widening participation would be key in enhancing bioinformatics and genomics research in Africa. <i>Applied & Translational Genomics</i> , 2015, 6, 35-41.	2.1	4
250	Neurogenomics: Challenges and opportunities for Ghana. <i>Applied & Translational Genomics</i> , 2015, 5, 11-14.	2.1	4
251	Inflammatory changes in very early Alzheimer's disease: friend, foe, or don't know?. <i>Brain</i> , 2016, 139, 647-650.	3.7	4
252	The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 767-775.	1.4	4

#	ARTICLE	IF	CITATIONS
253	APOE ϵ 4 carriers have superior recall on the "What was where?" visual short-term memory binding test at age 70, despite a detrimental effect of β -amyloid. <i>Alzheimer's and Dementia</i> , 2020, 16, e041090.	0.4	4
254	CSF phosphorylated tau ϵ 217 is increased in Alzheimer's and Creutzfeldt-Jakob diseases and correlates with amyloid pathology. <i>Alzheimer's and Dementia</i> , 2020, 16, e045296.	0.4	4
255	Olfactory testing does not predict β -amyloid, MRI measures of neurodegeneration or vascular pathology in the British 1946 birth cohort. <i>Journal of Neurology</i> , 2020, 267, 3329-3336.	1.8	4
256	Truncating tau reveals different pathophysiological actions of oligomers in single neurons. <i>Communications Biology</i> , 2021, 4, 1265.	2.0	4
257	Investigating the use of plasma pTau181 in retired contact sports athletes. <i>Journal of Neurology</i> , 2022, 269, 5582-5595.	1.8	4
258	O2 ϵ 05 ϵ 01: A DATA-DRIVEN MODEL OF BIOMARKER CHANGES IN SPORADIC ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2014, 10, P172.	0.4	3
259	An ethanolic extract of <i>Desmodium adscendens</i> exhibits antipsychotic-like activity in mice. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2017, 28, 507-518.	0.7	3
260	International Science Education. <i>Journal of Microbiology and Biology Education</i> , 2019, 20, 10.	0.5	3
261	Diet quality in late midlife is associated with faster walking speed in later life in women, but not men: findings from a prospective British birth cohort. <i>British Journal of Nutrition</i> , 2020, 123, 913-921.	1.2	3
262	How to diagnose difficult white matter disorders. <i>Practical Neurology</i> , 2020, 20, 280-286.	0.5	3
263	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. <i>Movement Disorders</i> , 2021, 36, 632-641.	2.2	3
264	When dementia is misdiagnosed. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 799-801.	1.3	3
265	Kenya and Ghana set up national research funding schemes. <i>Nature</i> , 2018, 557, 166-166.	13.7	3
266	Developing Science Communication in Africa: Undergraduate and Graduate Students should be Trained and Actively Involved in Outreach Activity Development and Implementation. <i>Journal of Undergraduate Neuroscience Education: JUNE: A Publication of FUN, Faculty for Undergraduate Neuroscience</i> , 2016, 14, E5-8.	0.6	3
267	A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12270.	1.8	3
268	CSF biomarkers for dementia. <i>Practical Neurology</i> , 2022, 22, 285-294.	0.5	3
269	Build the Future of Science Communication in Developing Countries through Systematic Training of Young Scientists. <i>Journal of Microbiology and Biology Education</i> , 2016, 17, 327-328.	0.5	2
270	Imaging the ageing brain: identifying early disease or opening Pandora's box?. <i>Lancet Neurology</i> , The, 2017, 16, 411-413.	4.9	2

#	ARTICLE	IF	CITATIONS
271	Cognitive decline before diagnosis of Parkinson's disease – Authors' reply. <i>Lancet Neurology</i> , The, 2017, 16, 262.	4.9	2
272	[ICaPa154]: CHARACTERISING THE PROGRESSION OF ALZHEIMER'S DISEASE SUBTYPES USING SUBTYPE AND STAGE INFERENCE (SUSTAIN). <i>Alzheimer's and Dementia</i> , 2017, 13, P116.	0.4	2
273	A Model Approach to Public Engagement Training for Students in Developing Countries. <i>Journal of Microbiology and Biology Education</i> , 2017, 18, .	0.5	2
274	Alzheimer's disease biomarker roadmap 2020: Fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2020, 16, e039557.	0.4	2
275	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e047539.	0.4	2
276	<i>Synedrella nodiflora</i> Extract Depresses Excitatory Synaptic Transmission and Chemically-Induced In Vitro Seizures in the Rat Hippocampus. <i>Frontiers in Pharmacology</i> , 2021, 12, 610025.	1.6	2
277	Reply: Functional cognitive disorder: dementia's blind spot. <i>Brain</i> , 2021, 144, e73.	3.7	2
278	A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	2
279	Study Protocol – Insight 46 Cardiovascular: A Sub-study of the MRC National Survey of Health and Development. <i>Artery Research</i> , 2020, 26, 170-179.	0.3	2
280	Distinctive effect of biological sex in AD-related CSF and plasma biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
281	The heterogeneous brain: Mapping individualised patterns of atrophy in Alzheimer's disease using spatial normative models. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
282	Familial British dementia: a clinical and multi-modal imaging case study. <i>Journal of Neurology</i> , 2022, 269, 3926-3930.	1.8	2
283	Factors influencing resilience to postoperative delirium in adults undergoing elective orthopaedic surgery. <i>British Journal of Surgery</i> , 0, , .	0.1	2
284	P1-286: STRATIFICATION OF DEMENTIA SUB-TYPES USING ARTERIAL SPIN LABELED MRI. , 2014, 10, P414-P415.		1
285	O2-14-06: ABNORMALITIES OF FIXATION, SACCADIC, AND PURSUIT IN POSTERIOR CORTICAL ATROPHY COMPARED TO TYPICAL AD. , 2014, 10, P199-P199.		1
286	Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy. <i>Clinical Neurology and Neurosurgery</i> , 2016, 144, 64-66.	0.6	1
287	[P1a443]: MULTIPLE DISTINCT ATROPHY PATTERNS FOUND IN GENETIC FRONTOTEMPORAL DEMENTIA USING SUBTYPE AND STAGE INFERENCE (SUSTAIN). <i>Alzheimer's and Dementia</i> , 2017, 13, P453.	0.4	1
288	[ICaPa047]: THE ROLE OF HIPPOCAMPAL SUBFIELDS IN THE ATROPHY PROCESS IN ALZHEIMER'S DISEASE: AN IN-VIVO STUDY OF THE ADNI COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P40.	0.4	1

#	ARTICLE	IF	CITATIONS
289	[O1â€“10â€“03]: BIOMARKERS OF INFLAMMATION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P215.	0.4	1
290	P2â€“890: DIFFERENTIAL HIPPOCAMPAL SUBFIELD LOSS IN DIFFERENT PHENOTYPES OF YOUNG ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P850.	0.4	1
291	O3â€“10â€“04: GENOMEWIDE ASSOCIATION STUDY OF DATAâ€“DRIVEN ALZHEIMER'S DISEASE SUBTYPES. Alzheimer's and Dementia, 2018, 14, P1042.	0.4	1
292	O2â€“05â€“01: INFLUENCES OF BLOOD PRESSURE AND BLOOD PRESSURE TRAJECTORIES ON CEREBRAL PATHOLOGY AT AGE 70: RESULTS FROM A BRITISH BIRTH COHORT. Alzheimer's and Dementia, 2018, 14, P626.	0.4	1
293	P1â€“031: HEAD INJURY WITH LOSS OF CONSCIOUSNESS AND SUBSEQUENT COGNITIVE DECLINE: FOLLOWâ€“UP IN THE 1946 BRITISH BIRTH COHORT STUDY. Alzheimer's and Dementia, 2018, 14, P278.	0.4	1
294	Looking beyond the eyes: visual impairment in posterior cortical atrophy. Lancet, The, 2019, 394, 1055.	6.3	1
295	The differential genetic architecture between posterior cortical atrophy and amnesic Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e038851.	0.4	1
296	Lifetime cigarette smoking and laterâ€“life brain health: The populationâ€“based 1946 British Birth Cohort. Alzheimer's and Dementia, 2020, 16, e041111.	0.4	1
297	Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimerâ€™s disease in the absence of AT(N) classification as the reference standard. Alzheimer's and Dementia, 2020, 16, e041808.	0.4	1
298	Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology. Alzheimer's and Dementia, 2020, 16, e041849.	0.4	1
299	Multimodal modelling of the heterogeneity of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e045822.	0.4	1
300	Serum neurofilament light and whole brain volume associate with machineâ€“learning derived brainâ€“predicted age in the British 1946 birth cohort. Alzheimer's and Dementia, 2020, 16, e045965.	0.4	1
301	Sex-related differences in whole brain volumes at age 70 in association with hyperglycemia during adult life. Neurobiology of Aging, 2021, 112, 161-169.	1.5	1
302	[P2â€“409]: THE ROLE OF HIPPOCAMPAL SUBFIELDS IN THE ATROPHY PROCESS IN ALZHEIMER'S DISEASE: AN INâ€“VIVO STUDY OF THE ADNI COHORT. Alzheimer's and Dementia, 2017, 13, P788.	0.4	1
303	Plasma pâ€“tau181 and pâ€“tau231 offer complementary information to identify Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2021, 17, .	0.4	1
304	Impact of polygenic risk score on normative models of hippocampal volumes. Alzheimer's and Dementia, 2021, 17, .	0.4	1
305	Combining biomarkers: the future for Alzheimerâ€™s disease prevention studies?. Neurodegenerative Disease Management, 2011, 1, 175-178.	1.2	0
306	P1-020: AUDITORY SPATIAL PROCESSING IN ALZHEIMER'S DISEASE AND POSTERIOR CORTICAL ATROPHY. , 2014, 10, P311-P311.		0

#	ARTICLE	IF	CITATIONS
307	IC-P-057: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POST MORTEM CONFIRMED DEMENTIAS. , 2014, 10, P32-P33.		0
308	P1-346: IDENTIFICATION OF ENVIRONMENTAL SOUNDS AND MELODIES IN SYNDROMES OF ANTERIOR TEMPORAL LOBE DEGENERATION. , 2014, 10, P440-P440.		0
309	P2-190: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POSTMORTEM CONFIRMED DEMENTIAS. , 2014, 10, P540-P541.		0
310	P4-189: Effect of brain-specific kinase-dependent tau phosphorylation on tauopathy-associated sundowning sleep behaviour. , 2015, 11, P852-P852.		0
311	Picturing the torment of cluster headache. <i>Neurology</i> , 2015, 85, 1430-1431.	1.5	0
312	[ICâ€Pâ€004]: A COMPARISON OF TECHNIQUES FOR QUANTIFYING AMYLOID BURDEN ON A COMBINED PET/MR SCANNER. <i>Alzheimer's and Dementia</i> , 2017, 13, P12.	0.4	0
313	[P4â€261]: LONGITUDINAL EVALUATION OF NEUROPSYCHOLOGICAL AND NEUROIMAGING PROGRESSION IN POSTERIOR CORTICAL ATROPHY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1382.	0.4	0
314	[ICâ€Pâ€079]: MULTIPLE DISTINCT ATROPHY PATTERNS FOUND IN GENETIC FRONTOTEMPORAL DEMENTIA USING SUBTYPE AND STAGE INFERENCE (SUSTAIN). <i>Alzheimer's and Dementia</i> , 2017, 13, P65.	0.4	0
315	[P2â€414]: CHARACTERISING THE PROGRESSION OF ALZHEIMER'S DISEASE SUBTYPES USING SUBTYPE AND STAGE INFERENCE (SUSTAIN). <i>Alzheimer's and Dementia</i> , 2017, 13, P791.	0.4	0
316	[P2â€545]: VASCULAR AND EARLY LIFE INFLUENCES ON CEREBROVASCULAR DISEASE IN INSIGHT 46: A SUBâ€STUDY OF THE MRC NATIONAL SURVEY OF HEALTH AND DEVELOPMENT (NSHD) BRITISH BIRTH COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P851.	0.4	0
317	[P3â€348]: EXPLORING THE POPULATION PREVALENCE OF Î²â€AMYLOID BURDEN: AN ANALYSIS OF 250 INDIVIDUALS BORN IN MAINLAND BRITAIN IN THE SAME WEEK IN 1946. <i>Alzheimer's and Dementia</i> , 2017, 13, P1088.	0.4	0
318	[P3â€373]: A COMPARISON OF TECHNIQUES FOR QUANTIFYING AMYLOID BURDEN ON A COMBINED PET/MR SCANNER. <i>Alzheimer's and Dementia</i> , 2017, 13, P1100.	0.4	0
319	[P4â€230]: LONGITUDINAL NEURITE ORIENTATION DISPERSION AND DENSITY IMAGING IN YOUNGâ€ONSET ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1359.	0.4	0
320	[ICâ€Pâ€168]: LONGITUDINAL NEURITE ORIENTATION DISPERSION AND DENSITY IMAGING IN YOUNGâ€ONSET ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P127.	0.4	0
321	[P1â€335]: THEMES AND VARIATIONS IN PPA: A CLINICAL AND NEUROBIOLOGICAL ANALYSIS OF THE UCL COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P384.	0.4	0
322	[P1â€348]: CSF AÎ²42 CONCENTRATION INDEPENDENTLY PREDICTS POSTOPERATIVE DELIRIUM IN AN ELDERLY ELECTIVE ARTHROPLASTY POPULATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P390.	0.4	0
323	[P1â€465]: PROGRESSIVE CALLOSAL ATROPHY WITH STABLE MEMORY IMPAIRMENT IN FAMILIAL BRITISH DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P465.	0.4	0
324	[P2â€241]: CSF NEUROGRANIN IS INCREASED IN FAMILIAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P703.	0.4	0

#	ARTICLE	IF	CITATIONS
325	[O4â€“02â€“04]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1230.	0.4	0
326	[O5â€“05â€“04]: BRAIN VOLUME, CEREBRAL Î²â€“AMYLOID DEPOSITION, AND AGEING: A STUDY OF OVER 200 INDIVIDUALS BORN IN THE SAME WEEK IN 1946. <i>Alzheimer's and Dementia</i> , 2017, 13, P1464.	0.4	0
327	ICâ€“Pâ€“151: AN EVENTâ€“BASED MODEL OF ALZHEIMER'S DISEASE IN APOE+ SUBJECTS USING ROBUST BIOMARKERS OF VOLUMETRIC CHANGE IN REGIONAL BRAIN STRUCTURE. <i>Alzheimer's and Dementia</i> , 2018, 14, P129.	0.4	0
328	P3â€“196: DISTINCT CONFORMATIONS, AGGREGATION AND NEURONAL PROPAGATION OF DIFFERENT TAU STRAINS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1142.	0.4	0
329	P1â€“267: CEREBROSPINAL FLUID/PLASMA ALBUMIN RATIO PREDICTS POSTOPERATIVE DELIRIUM IN AN OLDER ELECTIVE ORTHOPAEDIC POPULATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P384.	0.4	0
330	P3â€“420: AN EVENT BASED MODEL OF ALZHEIMER'S DISEASE IN APOE+ SUBJECTS USING ROBUST BIOMARKERS OF VOLUMETRIC CHANGE IN REGIONAL BRAIN STRUCTURE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1268.	0.4	0
331	P1â€“188: MODELLING AMYLOID BETA PROFILES IN IPSCâ€“DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER'S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE. <i>Alzheimer's and Dementia</i> , 2018, 14, P350.	0.4	0
332	O2â€“04â€“04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P623.	0.4	0
333	O3â€“14â€“04: THE PROTEINâ€“TOâ€“PEPTIDE RATIO IMPROVES THE PERFORMANCE OF MICROTUBULEâ€“ASSOCIATED PROTEIN TAU IN CSF AS AN ALZHEIMER BIOMARKER. <i>Alzheimer's and Dementia</i> , 2018, 14, P1060.	0.4	0
334	P3â€“437: LONGITUDINAL CORTICAL THICKNESS IN SPORADIC YOUNG ONSET ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1281.	0.4	0
335	ICâ€“Pâ€“076: GENOMEWIDE ASSOCIATION STUDY OF DATAâ€“DRIVEN ALZHEIMER'S DISEASE SUBTYPES. <i>Alzheimer's and Dementia</i> , 2018, 14, P67.	0.4	0
336	P1â€“474: SURFACEâ€“BASED ANALYSIS OF CORTICAL GREY MATTER MICROSTRUCTURE IN YOUNGâ€“ONSET ALZHEIMER'S DISEASE USING NEURITE ORIENTATION DISPERSION AND DENSITY IMAGING (NODDI). <i>Alzheimer's and Dementia</i> , 2018, 14, P505.	0.4	0
337	P3â€“261: SERUM NEUROFILAMENT LIGHT CONCENTRATION AND PROGRESSION IN FAMILIAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1174.	0.4	0
338	P1â€“301: CERTAIN PLASMA Nâ€“TERMINAL TAU FRAGMENTS ARE ELEVATED IN AD AND ADâ€“MCI COMPARED TO CONTROLS. <i>Alzheimer's and Dementia</i> , 2018, 14, P405.	0.4	0
339	Navigating Genetic Influences on the Topography of Alzheimerâ€“s Disease. <i>Biological Psychiatry</i> , 2018, 84, 476-477.	0.7	0
340	Clinicopathological case: progressive somnolence and dementia in an accountant: when the shine rubs off the gold standard. <i>Practical Neurology</i> , 2018, 18, 505-512.	0.5	0
341	Aide-mÃ©moires in semantic dementia. <i>Practical Neurology</i> , 2018, 18, 334-335.	0.5	0
342	ICâ€“Pâ€“007: CENTILOID SCALE TRANSFORMATION OF FLORBETAPIR DATA ACQUIRED ON A PET/MR SCANNER. <i>Alzheimer's and Dementia</i> , 2019, 15, P17.	0.4	0

#	ARTICLE	IF	CITATIONS
343	P4â€90: ALZHEIMER'S DISEASE POLYGENIC BURDEN BEYOND APOE ACTS STRONGER ON TAU THAN ON AMYLOID. Alzheimer's and Dementia, 2019, 15, P1500.	0.4	0
344	O4â€13â€01: EARLY ADULTHOOD VASCULAR RISK STRONGLY PREDICTS BRAIN VOLUMES AND WHITE MATTER DISEASE, BUT NOT AMYLOID STATUS, AT AGE 69â€71 YEARS: EVIDENCE FROM A BRITISH BIRTH COHORT. Alzheimer's and Dementia, 2019, 15, P1269.	0.4	0
345	ICâ€Pâ€006: LONGITUDINAL RATES OF AMYLOID ACCUMULATION IN A 70â€YEAR OLD BRITISH BIRTH COHORT. Alzheimer's and Dementia, 2019, 15, P16.	0.4	0
346	Plasma phosphoâ€tau181 in over 400 cognitively healthy 69â€to 71â€yearâ€olds: Associations with cerebral amyloid, structural imaging and cognition in the Insight 46 study. Alzheimer's and Dementia, 2020, 16, e037848.	0.4	0
347	Vascular risk factors and amyloid pathology: Additive or interactive associations?. Alzheimer's and Dementia, 2020, 16, e037922.	0.4	0
348	Uncovering superficial white matter changes in youngâ€onset Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e039746.	0.4	0
349	Performance on the graded naming test in a populationâ€based sample of 72â€yearâ€olds: Associations with lifeâ€course predictors and Î²â€amyloid pathology. Alzheimer's and Dementia, 2020, 16, e040897.	0.4	0
350	Accelerated forgetting is sensitive to Î²â€amyloid pathology and cerebral atrophy in cognitively normal 72â€yearâ€olds. Alzheimer's and Dementia, 2020, 16, e040987.	0.4	0
351	Plasma phosphoâ€tau in familial Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042921.	0.4	0
352	Cerebral amyloid and white matter hyperintensity volume are independently associated with rates of cerebral atrophy in Insight 46, a subâ€study of the 1946 British birth cohort. Alzheimer's and Dementia, 2020, 16, e044924.	0.4	0
353	Augmenting cognitive assessment with instructionâ€less Eyeâ€tracking tests: A machine learning approach for detecting abnormal oculomotor biomarkers. Alzheimer's and Dementia, 2020, 16, e045318.	0.4	0
354	An extensive plasmid library for preparing tau variants and studying their functional biochemistry. Alzheimer's and Dementia, 2020, 16, e045387.	0.4	0
355	Augmenting cognitive assessment with instructionâ€less eyeâ€tracking tests: A machine learning approach for detecting abnormal oculomotor biomarkers. Alzheimer's and Dementia, 2020, 16, e045483.	0.4	0
356	Midâ€life blood pressure and microstructural white matter: Findings from the 1946 British birth cohort. Alzheimer's and Dementia, 2020, 16, e045707.	0.4	0
357	Comparison of static and dynamic analysis techniques for longitudinal analysis of amyloid PET. Alzheimer's and Dementia, 2020, 16, e045991.	0.4	0
358	Plasmaâ€based biomarkers for AÎ² and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e046490.	0.4	0
359	Association of plasma neurofilament light chain (pNfL) with neuroimaging markers of neurodegeneration and cerebrovascular disease. Alzheimer's and Dementia, 2020, 16, e043060.	0.4	0
360	A THREE-RANGE APPROACH ENHANCES PROGNOSTIC UTILITY OF CSF BIOMARKERS IN ALZHEIMERâ€™S DISEASE. , , .		0

#	ARTICLE	IF	CITATIONS
361	Developments in clinical testing of cerebrospinal fluid biomarkers of Alzheimer's disease in the UK. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
362	Menopause and later-life cognition: Findings from the longest-running population-based birth cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
363	Implementation of remote neuropsychological assessments in the Insight 46 study: Lessons learned from the transition to videoconferencing and telephone assessments. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
364	Atrophy and partial volume related bias in cortical region of interest NODDI metrics. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
365	Association of tau pathology and vascular risk factor burden with longitudinal measures of plasma neurofilament light. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
366	Plasma p-tau ₂₃₁ in the Alzheimer's disease continuum: A multi-cohort evaluation of diagnostic performance, detection of A β pathology and preclinical application. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
367	Disentangling axonal loss and demyelination using multi-modal imaging: Application to young onset Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
368	Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of patients with mixed pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
369	Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
370	Mass spectrometric measurement of six site-specific tau phosphorylations in CSF and blood of Alzheimer's disease patients. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
371	Plasma p-tau ₁₈₁ and NfL are central nodes in a network of diagnostic, biomarker, and demographic data. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
372	Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
373	CSF and blood biomarkers: How strongly do they reflect Alzheimer's pathophysiology and are they dynamic?. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
374	Fixel-based analysis of the effect of amyloid beta on white matter tracts in neurologically normal 70 year olds. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
375	Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
376	Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels in Down Syndrome and Sporadic Alzheimer's Disease: A Cross-Sectional Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
377	Title is missing!. , 2019, 14, e0224030.		0
378	Title is missing!. , 2019, 14, e0224030.		0

#	ARTICLE	IF	CITATIONS
379	Title is missing!. , 2019, 14, e0224030.		0
380	Title is missing!. , 2019, 14, e0224030.		0
381	Population-based blood screening for pre-clinical Alzheimer's disease: a British birth cohort at age 70. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A91.2-A91.	0.9	0
382	Editorial: Blood Biomarkers of Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	0